Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

About this update from Spruce Biosciences, Inc.

Accomplished Rare Disease Drug Developer Brings More Than 25 Years of Global Clinical Development and Medical Affairs Leadership, Including the Launch of Multiple Enzyme Replacement Therapies for Rare Pediatric and Genetic Disorders SOUTH SAN FRANCISCO, Calif., July 27, 2026--(BUSINESS WIRE)--Spruce Biosciences, Inc. ("Spruce Biosciences" or "Spruce") (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer, effective today. Dr. Quartel brings more than 25 years of experience in the international pharmaceutical industry, with senior roles spanning clinical development, pharmacovigilance and medical affairs, and a track record of advancing and launching enzyme replacement therapies for rare diseases. "Adrian's proven experience in rare disease drug development will be essential to the work ahead of us at Spruce as we set our sights on a BLA filing for tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) in Q4 2026 and prepare for a potential commercial launch," said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce Biosciences. "Having helped bring multiple enzyme replacement therapies to patients with rare pediatric and genetic disorders, including neurodegenerative disease, Adrian understands the clinical, regulatory and medical complexities of programs like ours. We are delighted to welcome Adrian to our executive leadership team." Dr. Quartel joins Spruce from Zevra Therapeutics, where he served as Chief Medical Officer and helped guide the clinical development, medical affairs and regulatory strategy for the company's rare disease portfolio. Prior to Zevra, he was Chief Medical Officer of Acer Therapeutics and Chief Medical Officer of Adamas Pharmaceuticals. Earlier, as Group Vice President of Global Medical Affairs at BioMarin Pharmaceutical, he spearheaded the launch of six treatments for rare diseases and genetic disorders, including the enzyme replacement therapies NAGLAZYME®, VIMIZIM® and Brineura®—the last of which is a therapy for a rare pediatric neurodegenerative disorder. Before BioMarin, Dr. Quartel oversaw clinical development and held senior medical leadership positions at A...

View stock analysis, news, and events for Spruce Biosciences, Inc.